Any severe or poorly controlled systemic disease (e.g., hypertension; clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound healing, ulcer or bone fracture)
Other clinically significant disorders such as:* Active infection requiring systemic treatment within 28 days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; participants with known hepatitis B infection should be screened for active disease prior to study participation; participants with known hepatitis C infection must not be actively receiving treatment for the infection* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment* History of organ transplant* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment* History of major surgery as follows:** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
Other clinically significant disorders such as:* Active uncontrolled infection requiring intravenous systemic treatment within 14 days before the first dose of study treatment* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment* History of organ transplant* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment* History of major surgery as follows:** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications*** In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
Serious or non-healing wound, ulcer or bone fracture
History of serious or non-healing wound, ulcer, or bone fracture
Other clinically significant disorders such as:* Severe active infection requiring systemic treatment within 28 days before the first dose of study treatment* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment* History of organ transplant* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)* History of major surgery as follows:** Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and Mediport placement* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
Patients who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment are not eligible
No history of serious non-healing wound, ulcer, or bone fractures
Non-healing wound, ulcer or bone fracture
Severe, active co-morbidity defined as follows:* Current (within 28 days of cycle 1, day 1) signs and/or symptoms of bowel obstruction* Patients who require parental hydration and/or nutrition* Patients who require drainage gastrostomy tube* Evidence of bleeding diathesis or clinically significant coagulopathy* Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture* History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment
At least 4 weeks must have elapsed since any surgeries, with evidence of completed wound healing
At least 4 weeks must have elapsed since any surgeries, with evidence of good wound healing
Patients with a non-healing wound, fracture, or ulcer
Serious or non-healing wound, active ulcer or bone fracture
History of serious or non-healing wound, ulcer, or bone fracture
Serious or non-healing wound, ulcer or bone fracture